Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 26, 2024
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various...
-
Feb 7, 2024
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death...
-
Jan 4, 2024
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave...
-
Dec 4, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave...
-
Oct 31, 2023
Poster presentation describes the development of SNAP CAR platform technology as a "universal" CAR therapy with the potential to target multiple antigens through combinatorial use of different...
-
Oct 24, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has...
-
Oct 11, 2023
Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis"...
-
Oct 9, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dan...
-
Oct 4, 2023
Poster to be presented by research team from University of Pittsburgh, led by Jason Lohmueller, Ph.D., Assistant Professor of Immunology WEXFORD, Pa. , Oct. 4, 2023 /PRNewswire/ -- Coeptis...
-
Sep 27, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Colleen...
-
Sep 14, 2023
DVX201, a first-ever allogeneic, cord-blood derived, natural killer (NK) cell therapy, has been administered to 16 patients with no dose limiting toxicities, cytokine release syndrome or infusion...
-
Sep 11, 2023
Grants totaling approximately $3.5 million will support Deverra's CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa., Sept. 11, 2023 /PRNewswire/...
-
Aug 30, 2023
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/...
-
Aug 17, 2023
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory...
-
Aug 1, 2023
513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa., Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the...
-
Jun 16, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of...
-
Jun 14, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of...
-
Jun 9, 2023
Trading to commence effective with the open of business on June 13, 2023 WEXFORD, Pa. , June 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the...
-
May 17, 2023
15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics...
-
May 10, 2023
SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor (CAR) T cells for various cancers and other indications WEXFORD, Pa., May 10, 2023...
-
Apr 18, 2023
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory...
-
Mar 29, 2023
Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD, Pa.
-
Mar 21, 2023
SNAP-CAR recognized in research detailing advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility WEXFORD, Pa., March 21, 2023 /PRNewswire
-
Feb 7, 2023
Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services WEXFORD, Pa., Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics...
-
Jan 31, 2023
Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis...